This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00013/identifier/drugbank/
n19http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00013/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n6http://www.drugs.com/mtm/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://www.rxlist.com/cgi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00013/identifier/uniprotkb/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00013/identifier/genbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00013/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00013/identifier/wikipedia/
n16http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00013
rdf:type
n3:Drug
n3:description
Low molecular weight form of human urokinase, that consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Recombinant urokinase plasminogen activator
n3:generalReferences
# Housley C: Contract purchasing means a buyer's market. Dimens Health Serv. 1976 Apr;53(4):16, 19-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/5328
n3:group
withdrawn investigational approved
n3:halfLife
12 minutes. Small fractions of the administered dose are excreted in bile and urine
n3:indication
Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.
n3:manufacturer
n11:271B3F32-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00013 n19:DB00013
dcterms:title
Urokinase
adms:identifier
n18:Urokinase n20:PA451836 n21:P00749 n22:X02419 n23:24430-1003-1 n24:DB00013
n3:mechanismOfAction
Urokinase acts on the endogenous fibrinolytic system. It cleaves the Arg-Val bond in plasminogen to produce active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins.
n3:packager
n11:271B3F31-363D-11E5-9242-09173F13E4C5 n11:271B3F2F-363D-11E5-9242-09173F13E4C5 n11:271B3F30-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Urokinase administered by intravenous infusion is rapidly cleared by the liver. Small fractions of the administered dose are excreted in bile and urine
n3:synonym
U-plasminogen activator Urokinase-type plasminogen activator precursor uPA
n12:hasAHFSCode
n13:20-12-20
n3:synthesisReference
Koji Sasaki, Yasukazu Harada, "Urokinase preparation for oral administration." U.S. Patent US4258030, issued November, 1975.
n14:hasConcept
n15:M0022396
foaf:page
n6:urokinase.html n8:pharmclips2.cgi?keyword=%20Abbokinase%AE
n3:Molecular-Formula
n4:271B3F37-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F36-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n16:B01AD04
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
9039-53-6
n3:category
n3:Hydrophobicity
n4:271B3F34-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n4:271B3F35-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3F33-363D-11E5-9242-09173F13E4C5